Powering Alzheimer’s research with AI-driven insights across cognition, meaning, motor function, and speech — accelerating study recruitment and enabling more equitable, personalized brain health care
Linus Health, which is revolutionizing brain health with science-driven digital solutions, will present two oral presentations and eight posters at the Alzheimer’s Association International Conference® (AAIC®) 2025, taking place July 27-31 in Toronto and virtually.
Linus Health will be onsite at Booth #1219 to showcase its AI-powered digital cognitive assessment solutions and preview enhancements to its life sciences research platform. AAIC attendees will also receive a first look at new platform solutions and capabilities that enable remote use by patients and participants at home, part of the company’s broader vision to bring proactive brain health support directly into people’s hands.
Linus Health’s AAIC 2025 research program underscores its commitment to bringing actionable scientific findings to the forefront of brain health by presenting research on novel applications of AI in dementia detection, new insights into the clinical relevance of digital cognitive assessments, and tools to improve trial recruitment and patient engagement.
“The studies we are presenting at AAIC 2025 represent the next wave of translational science in brain health,” said Linus Health CEO and Co-Founder David Bates, PhD. “By combining validated digital tools with AI, we are enabling earlier and more accurate detection of mild cognitive impairment, Alzheimer’s disease, and related dementias. At the same time, we are expanding access to proactive brain health support through at-home solutions that empower individuals to engage in their cognitive health journey, helping improve patient outcomes and clinical trial efficiency alike.”
Some of the hottest topics coming from Linus Health at this year’s AAIC include:
- Machine Learning-Enabled Digital Cognitive Assessment to Streamline Clinical Trial Recruitment
Linus Health Director of Cognitive Science Ali Jannati, MD, PhD, will present several findings, including a developing topics session on the concurrent detection of cognitive impairment and amyloid-beta PET status using Linus Health’s Digital Clock and Recall. The machine-learning model aims to streamline pre-screening for Alzheimer’s disease trials by reducing participant burden and increasing accuracy in identifying trial-eligible populations. - Multi-Modal AI Models for Detecting Cognitive Impairment and Predicting AD Pathology
Several posters from the Linus team explore the power of combining digital assessments with blood-based biomarkers and stylus/voice-derived features to predict amyloid-beta PET status and detect cognitive impairment. - Advances in Personalization and Population Engagement
Other posters examine novel methods for personalized brain health recommendations based on individual values and preferences using language models and explore how semi-supervised clustering can identify cognitive subgroups in large populations. - Validation of Digital Cognitive Metrics in Clinical and Research Settings
David Libon, PhD, Linus Health Scientific Advisor and neuropsychology researcher, will present three posters investigating the clinical relevance of digital trail-making metrics and their relationship to motor versus cognitive impairments, as well as paper-and-pencil tests and abbreviated versions optimized for digital use.
“For decades, we have recognized that examining the process of how someone performs a cognitive test is just as important as whether they get the answers right,” said Libon. “Our research shows how digital tools can quantify these nuances and bring a more neuropsychologically grounded approach to brain health assessment, and, importantly, one that scales from clinical trials to primary care.”
Additional details on Linus Health’s AAIC 2025 poster presentations and sessions include:
Saturday, July 26 (Alzheimer’s Imaging Consortium Preconference)
- An Abbreviated Version of the Digital Trail Making Test-Part B – David Libon, PhD
- Separating Neurocognitive versus Motor Disabilities with the Digital Trail Making Test-Part B – David Libon, PhD
Sunday, July 27
- Concurrent Detection of Cognitive Impairment and Amyloid-Beta PET Status with a Combination of Digital Clock and Recall and Digital Trail Making Test-Part B – Ali Jannati, MD, PhD
Monday, July 28
- Exploratory Semi-Supervised Clustering to Identify Dementia and MCI Cohorts – Tanya Talkar, PhD
- Leveraging Language Models to Categorize Individual-Level Priorities for Personalized Brain Health – Ali Jannati, MD, PhD
- Identification of MCI with Traditional, Process, and Acoustic Metrics – Tanya Talkar, PhD
Tuesday, July 29
- Oral presentation: Streamlining Recruitment for AD Clinical Trials: Concurrent Detection of Cognitive Impairment and Amyloid-Beta PET Status with a Machine Learning-Enabled Digital Cognitive Assessment – Ali Jannati, MD, PhD
- Oral presentation: Relationship Between the Digital Assessment of Cognition Paper and Pencil Neuropsychological Tests – David Libon, PhD
- Prediction of Amyloid-Beta PET Status Using Multi-Modal Metrics and Blood-Based Biomarkers – Ali Jannati, MD, PhD
- Separating Neurocognitive versus Motor Disabilities with the Digital Trail Making Test-Part B – David Libon, PhD
Wednesday, July 30
- The Digital Clock and Recall and Its Relationship to Standard Assessments: Insights from UK SBS-IONA – Ali Jannati, MD, PhD
- An Abbreviated Version of the Digital Trail Making Test-Part B – David Libon, PhD
- Relationship Between Digital and Paper-and-Pencil Neuropsychological Tests – David Libon, PhD